The stock of Viracta Therapeutics Inc (VIRX) has gone down by -6.80% for the week, with a -38.67% drop in the past month and a -36.42% drop in the past quarter. The volatility ratio for the week is 8.24%, and the volatility levels for the past 30 days are 9.68% for VIRX. The simple moving average for the past 20 days is -17.08% for VIRX’s stock, with a -73.97% simple moving average for the past 200 days.
Is It Worth Investing in Viracta Therapeutics Inc (NASDAQ: VIRX) Right Now?
Company’s 36-month beta value is 0.70.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VIRX is 27.94M, and currently, short sellers hold a 9.63% ratio of that floaft. The average trading volume of VIRX on November 27, 2024 was 1.06M shares.
VIRX) stock’s latest price update
The stock of Viracta Therapeutics Inc (NASDAQ: VIRX) has decreased by -8.00 when compared to last closing price of 0.16.Despite this, the company has seen a loss of -6.80% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that – Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) –
Analysts’ Opinion of VIRX
Many brokerage firms have already submitted their reports for VIRX stocks, with Leerink Partners repeating the rating for VIRX by listing it as a “Market Perform.” The predicted price for VIRX in the upcoming period, according to Leerink Partners is $3 based on the research report published on August 16, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see VIRX reach a price target of $10. The rating they have provided for VIRX stocks is “Outperform” according to the report published on February 01st, 2022.
H.C. Wainwright gave a rating of “Buy” to VIRX, setting the target price at $35 in the report published on May 03rd of the previous year.
VIRX Trading at -30.95% from the 50-Day Moving Average
After a stumble in the market that brought VIRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.11% of loss for the given period.
Volatility was left at 9.68%, however, over the last 30 days, the volatility rate increased by 8.24%, as shares sank -35.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.18% lower at present.
During the last 5 trading sessions, VIRX fell by -6.80%, which changed the moving average for the period of 200-days by -77.93% in comparison to the 20-day moving average, which settled at $0.1720. In addition, Viracta Therapeutics Inc saw -74.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIRX starting from Chevallard Daniel R., who sale 3,405 shares at the price of $0.73 back on Feb 27 ’24. After this action, Chevallard Daniel R. now owns 102,306 shares of Viracta Therapeutics Inc, valued at $2,493 using the latest closing price.
Rothera Mark, the President and CEO of Viracta Therapeutics Inc, purchase 52,094 shares at $0.49 during a trade that took place back on Nov 30 ’23, which means that Rothera Mark is holding 52,094 shares at $25,734 based on the most recent closing price.
Stock Fundamentals for VIRX
Current profitability levels for the company are sitting at:
- -63.97 for the present operating margin
- 0.55 for the gross margin
The net margin for Viracta Therapeutics Inc stands at -58.66. The total capital return value is set at 7.13. Equity return is now at value -370.13, with -97.94 for asset returns.
Based on Viracta Therapeutics Inc (VIRX), the company’s capital structure generated 1.64 points at debt to capital in total, while cash flow to debt ratio is standing at -2.06. The debt to equity ratio resting at -2.56. The interest coverage ratio of the stock is -14.83.
Currently, EBITDA for the company is -46.86 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 12.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.76.
Conclusion
In a nutshell, Viracta Therapeutics Inc (VIRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
